

| Phone: 888-417-5780 | Fax: 877-427-7290 | M-F, 8AM to 5PM EST |

Please complete application in full, sign and date, then fax to: 877-427-7290

Or email to: ViatrisPAP@viatris.com

- The PAP Application must be complete to be reviewed for patient program eligibility. Please ensure all areas of the form are completed in full, including all signatures.
- To be considered for the Viatris Patient Assistance Program, all applicants must satisfy the following requirements and eligibility criteria:
 - o Applicants qualify for the program financial requirements.
 - Applicants must be a current United States resident (includes U.S Territories).
 - Applicant must be fully uninsured or if insured, have no prescription drug insurance.
 - The requested product must be prescribed by a licensed U.S. healthcare professional for a Food and Drug Administration (FDA) approved indication.
- Each applicant will be individually assessed for program eligibility based on the information provided within this application.
- Applicants will only be evaluated for eligibility upon receipt of a completed and signed Viatris Patient Assistance Program (PAP) Application.



| Phone: 888-417-5780 | Fax: 877-427-7290 | M-F, 8AM to 5PM EST |



Patient Information			
Name:			
Home Phone: Cell Phone:	Patient Email	Address:	
Preferred Contact: Cell Phone Home Phone En	nail Best Time to Call: Morni	ng Afternoon Evening	Gender:
Insurance: Uninsured Commercial Gover	rnment	Rx Coverage: Yes	□ No
Insurance Name: Insura	ance ID Number:	*No F	O Boxes Accepted
Prescriber Information			
Prescriber Name:		Prescriber NPI:	
Facility Name:		State License #:	
Facility Address:	City:	State:	ZIP:
Primary Office Contact:		Fax Number:	
Phone Number: Office Co	ontact Email:		
Prescriber Shipping Address (Only complete	te if shipping address is diffe	erent than address listed a	bove)
Prescriber Name:		Facility Name:	
Shipping Address:	City:	State:	ZIP:
Shipment Contact Name:			
Phone Number: C	ontact Email:		



| Phone: 888-417-5780 | Fax: 877-427-7290 | M-F, 8AM to 5PM EST |



Ohio Prescriber Mandatory Subsection (Select an option below, complete the related fields, then sign & date)!

MANDATORY SUBSECTION FOR ALL OHIO HCPs

Under Ohio law, Mylan Pharmaceuticals Inc., a Viatris Company, may only provide prescription drugs to a prescriber whose practice is licensed as a Terminal Distributor of Dangerous Drugs ("TDDD") or is exempt from such licensure under Ohio Revised Code ("ORC") § 4729.541. A TDDD license allows a business entity to receive, purchase, and possess prescription drugs, including drug samples, for distribution to patients. For more information on TDDD licensing requirements for prescribers, please visit the Ohio Board of Pharmacy website at www.pharmacy.ohio.gov/PrescriberTDDD , and for a list of exemptions, please refer to section 4729.541 of the ORC. The above information is being provided for your convenience and is not offered, nor should it be construed, as legal advice.					
Please sel	lect and complete one of the following and	l sign below:			
	The practice at which I work,	, located at the address I provided above, has an active TDDD license that			
	allows me to receive and store the requested prescription drug products at this location. The TDDD license number is				
-OR-					
	The practice at which I work,licensing exemptions in ORC § 4729.541.	, located at the address I provided above, is subject to one of the TDDD			
By signing below, I warrant that the information provided above is complete and accurate and attest that I can receive and store the requested prescription drug products at the address I provided because I hold an unrestricted, active TDDD license or my practice is exempt from obtaining a TDDD license under ORC § 4729.541.					
Prescriber		Date:			
(Original signature -and- date required, stamped signatures not accepted)					



| Phone: 888-417-5780 | Fax: 877-427-7290 | M-F, 8am to 5pm EST |



Arixtra® (fondaparinux sodium) injection, solution		
2.5mg/0.5mL PFS 10PK		
QTY		
5		
5mg/0.4mL PFS 10PK		
QTY		
7.5		
7.5mg/0.6mL PFS 10PK		
QTY		
40ma (0.0m) DEC 40DV		
10mg/0.8mL PFS 10PK		
QTY		
DDEVNATM (budgespide and formatoral		
BREYNA™ (budesonide and formoterol		
fumarate dihydrate) Inhalation Aerosol		
80mcg/4.5mcg		
QTY		
160mcg/4.5mcg		
QTY		
Cortifoam® (hydrocortisone acetate 10%)		
rectal foam		
10% 15g		
QTY		
411		
Cysta gon® (Cysteamine bitartrate) capsules		
50mg C 500s		
QTY		
150mg C 500s		
QTY		
Denavir® (penciclovir) Cream		
1% 5gm		
QTY		
Dipentum® (olsalazine sodium) capsule		
250mg C 100s		
QTY		
Dymista® azelastine hydrochloride &		
fluticasone propionate) nasal spray		
137/50mcg Nasal Spray 23g		
QTY		

EMSAM® Transdermal System
12 mg/24 hr Bx30
QTY
6 mg/24 hr Bx30
QTY
Q11
TDS 9 mg/24 hr Bx30
QTY
ERMEZA™ (levothyroxine sodium) oral
solution
150 mcg/5mL) 150mL
QTY TOSTILE
150 mcg/5mL) 75mL
QTY
Felbatol® (felbamate)
400mg T 100s
QTY
000 T 400-
600mg T 100s
QTY
600mg OS 8oz
QTY
600mg OS 32oz
QTY
Gastrocrom® (cromolyn sodium, USP) oral concentrate
100mg 5mL Oral Concentrate 96s
QTY
Miacalcin® Injection
200 IU/mL 2mL MDV 1pk
QTY
Muse® (alprostadil) urethral
250mcg Suppository 6s
QTY
500mcg Suppository 6s
QTY
1000mcg Suppository 6s
QTY

Perforomist® (formoterol fumarate) Inhalation Solution		
20 mcg / 2 mL 30x1		
QTY		
20 mcg / 2 mL 60x1		
QTY		
Pretomanid Tablets		
200mg T 26		
QTY		
Proctofoam® HC (hydrocortisone acetate 1%		
and pramoxine hydrochloride 1%)		
HC 1% 10g		
ROWASA® (mesalamine) Rectal Suspension		
60mL Rectal Susp 7s		
QTY		
60mL Rectal Susp 28s		
QTY		
sfROWASA® (mesalamine) Rectal Suspension		
60mL Rectal Susp 7s		
aty		
60mL Rectal Susp 28s		
QTY		
Wixela Inhub® (fluticasone propionate and salmeterol inhalation powder, USP)		
100mcg/50mcg 60/lnh		
QTY		
250mcg/50mcg 60/lnh		
QTY		
500mcg/50mcg 60/lnh		
QTY		
XULANE® (norelgestromin and ethinyl estradiol transdermal system)		
TDS 0.15mg/0.035mg/QD 3s		
QTY		
Yupelri® (revefenacin) inhalation solution		
175mcg / 3mL 30s		
QTY		



Viatris Patient Assistance Program Application | Phone: 888-417-5780 | Fax: 877-427-7290 | M-F, 8AM to 5PM EST



Prescription Details- Please complete all relevant prescription details below				
Patient Name:	Patient DOB:			
Prescriber Name:	Prescriber NPI:			
Day Supply:				
D: #				
Prescriber Certification and Prescri	intion Signature			
product I have prescribed to the applicant with Administration (FDA) approved indication, and the isingly not be applied to the applicant of my patient's personal identification and insurant I understand that any information provided to ward representatives to verify my patient's insurance (collectively, "the Program"), and to other guarantee that assistance will be obtained. I understand that Viatris may change or cancel patient may no longer be eligible for the Programiland/or telephone. I understand that I am unfrom Viatris or its agents or representatives for reimbursement from any third party for any proceeding the Surescriber acknowledges that in connection with using the Surescripts retwork. Surescripts required that I messaging, privacy and security, a available at https://ubc.com/surescriptsterms/. By signing this Patient Assistance Program App of Viatris to use and disclose as necessary for very patient in the patient in the program and the program and the program and disclose as necessary for very patient in the program and the program and the program and disclose as necessary for very patient in the program and the pro	ent Assistance Program Application is complete and accurate to the best of my knowledge, that the Viatris thin this application is based on my professional judgment of medical necessity for a Food and Drug that I will supervise the patient's medical treatment. I will notify Viatris PAP immediately if the Viatris product 's treatment. I certify that I have obtained from my patient all required written authorizations for the release ance information to Viatris and their agents and representatives. In a significant of the release of Viatris and their agents, service providers, rance coverage status, to assess the patient's eligibility for participation in the Viatris Patient Assistance nerwise administer the product and related services. I understand that application to the Program does not this program at any time. I understand that if my patient's financial and/or insurance status changes, the am, and I agree to immediately notify a Viatris PAP representative if I become aware of changes in the ree that Viatris PAP may contact me for additional information relating to this application either by fax, eder no obligation to prescribe any Viatris product and that I have not received, nor will I receive, any benefit represcribing a Viatris product. I agree that I will not sell, submit claims or make any attempt to receive duct provided by the Program. If the application and enrollment process, United BioSource Corporation (UBC) performs eligibility screening uires that Prescriber agree to comply with all Surescripts' terms and conditions, including confidentiality, applicable laws, and use of data. All Surescripts disclaimers apply. A full list of terms and conditions is verification, I authorize the release of medical and/or other patient information to agents and service providers verification of patient eligibility, and to furnish any information on this form to the insurer of the applicant for erstand that Program duration per eligibility period is 12 months, and the maximum number of refills per			
eligible patient is 11 for each unique enrollment				
Prescriber Certification & Prescription Signatur	re: Date:			



| Phone: 888-417-5780 | Fax: 877-427-7290 | M-F, 8AM to 5PM EST |



Patient Authorization and Agreement Signature

By signing this Authorization, I authorize each of my physicians, pharmacists, including any non-commercial pharmacy that receives my prescription ("my Prescribed Product"), and other healthcare providers (together "Healthcare Providers") and each of my health insurers, if any (together, "Insurers") to disclose my Protected Health Information, including but not limited to medical records, information related to my medical condition and treatment, my health insurance coverage, my name, address, telephone number, Social Security number, insurance plan and or group numbers (together, "Protected Health Information") to Viatris, its affiliated companies, vendors, agents, collaboration partners, and representatives (together, "Viatris") including providers of alternate sources of funding for prescription drug costs, and other service providers supporting the Viatris Patient Assistance Program (PAP) (collectively, the "Program") for the purposes described below.

Specifically, I authorize disclosure of my Protected Health Information in order to:

- I. Enroll me in, and contact me about the Program, including online support, financial assistance services, and co-pay assistance services, as applicable,
- II. Communicate with my Healthcare Providers and Insurers about benefits, coverage, and medical care, including compliance with Product treatments,
- III. Facilitate dispensing of my prescription by a non-commercial pharmacy,
- IV. Provide me with educational materials, information and services related to my treatment experience with my prescribed medication and my condition,
- V. Verify, investigate, and coordinate with my Insurers regarding my prescribed medication, and
- VI. Contact me as otherwise required or permitted by law.

Once my Protected Health Information has been disclosed to Viatris, I understand that federal privacy laws no longer protect the information. However, Viatris agrees to protect my Protected Health Information by using and disclosing it only for the purposes described in this Authorization or as permitted by law. I understand that I may refuse to sign this Authorization. My choice about whether to sign will not change the way my Healthcare Providers or Insurers treat me, but I will not have access to the Viatris Patient Assistance Program and the services provided by Viatris under the Program. If I refuse to sign the Authorization, or revoke my Authorization later, I understand that this means I will not be able to participate in or receive assistance from the Program.

I understand that my signed Authorization is valid for 5 years from the date of my signature, and that I may revoke this Authorization at any time in the future, except to the extent that actions have been taken in reliance on the Authorization. I understand that to revoke this Authorization I may mail a request to 5005 Greenbag Road Morgantown, WV 26508, fax to 877-427-7290, or by calling 888-417-5780. I understand that revoking this Authorization will end further uses and disclosure of my Protected Health Information by the parties identified above except to the extent those uses and disclosures have been made in reliance upon this Authorization as permitted by applicable law. I am entitled to receive a copy of this Authorization.

I understand that if I qualify and I am enrolled in the Program sponsored by Viatris, I will receive my Prescribed Product from Viatris only pursuant to a legally valid prescription from my health care provider. I understand that if I qualify and I am enrolled in the Program, Viatris will provide me my Prescribed Product free of charge for the duration of the enrollment period so long as I have a legally valid prescription for my Prescribed Product. I understand that I am not required to continue treatment with my Prescribed Product if I gain insurance coverage, or to receive treatment from any given provider. I understand and agree that I must notify Viatris PAP at 888-417-5780 immediately if my insurance status changes during the Program enrollment period. I understand and agree that neither I nor my Insurers, if applicable, will be charged for the supply of my Prescribed Product that I received from the Program, and that under NO circumstances may I claim reimbursement from my Insurers or any other third party for the Prescribed Product provided to me free of charge from the Program. I understand that Viatris reserves the right at any time without notice to modify or discontinue the Program and its criteria.

I understand that I am providing 'written instructions' to Viatris under the Fair Credit Reporting Act authorizing Experian on behalf of Viatris to obtain information from my credit profile or other information from Experian. I authorize Viatris and its service providers to obtain such information solely for the purpose of determining financial qualifications for the Program. I understand that I must affirmatively agree to the terms in this notice by signing below in order to proceed in the Program financial screening process.

My signature certifies that I have read and understand the above statements and agree to the outlined terms.

5 4 6 4

Patient Name (Print):	Patient Signature	·	Date:
Patient Authorized Representat	ive		
I permit Viatris PAP Support Services repremy application, insurance and financial que issues. I may cancel this Patient Authorized	estions, any missing documentatio	n and other issues related to my enr	
Name of Authorized Representative:		Relationship to Patient:	
Telephone Number:	Email:		
By signing below, I, the patient, allow this re	epresentative to speak on my beha	alf on any matter regarding my enroll	ment with the Program.
Patient Signature:			Date:

